Halaven and C-reactive protein increased - a phase IV clinical study of FDA data

Summary:

C-reactive protein increased is reported as a side effect among people who take Halaven (eribulin mesylate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Decadron, and have Breast cancer.

The phase IV clinical study analyzes which people have C-reactive protein increased when taking Halaven. It is created by eHealthMe based on reports of 3,873 people who have side effects when taking Halaven from the FDA, and is updated regularly.

What is Halaven?

Halaven has active ingredients of eribulin mesylate. eHealthMe is studying from 3,881 Halaven users. Check the latest studies of Halaven.

What is C-reactive protein increased?

C-reactive protein increased is found to be associated with 1,566 drugs and 2,281 conditions by eHealthMe. Check the latest studies of C-reactive protein increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

3,873 people reported to have side effects when taking Halaven.
Among them, 13 people (0.34%) have C-reactive protein increased.

Could Halaven cause C-reactive protein increased?

Among these 13 people:

How long have people been on Halaven when they have C-reactive protein increased? *

What is the gender of people who have C-reactive protein increased when taking Halaven? *

female: 84.62 %
male: 15.38 %

What is the age of people who have C-reactive protein increased when taking Halaven? *

What are other drugs people take besides Halaven? *

What are other side effects people have besides C-reactive protein increased? *

Leukopenia (less number of white blood cells in blood): 4 people, 30.77%
Fever: 4 people, 30.77%
Febrile Neutropenia (fever with reduced white blood cells): 3 people, 23.08%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 23.08%
Anaemia (lack of blood): 2 people, 15.38%
Nausea And Vomiting: 1 person, 7.69%
Malignant Neoplasm Progression (cancer tumour came back): 1 person, 7.69%
Infection: 1 person, 7.69%
Hyperbilirubinaemia (excess of bilirubin in the blood): 1 person, 7.69%
Hepatic Enzyme Increased: 1 person, 7.69%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 3 people, 23.08%
Breast Cancer: 3 people, 23.08%
Metastases To Skin (cancer spreads to skin): 2 people, 15.38%
Metastases To Lymph Nodes (cancer spreads to lymph node): 2 people, 15.38%
Metastases To Breast (cancer spreads to brain): 2 people, 15.38%
Breast Cancer Recurrent: 2 people, 15.38%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 1 person, 7.69%
Salivary Hypersecretion (excess saliva secretion): 1 person, 7.69%
Rhabdomyosarcoma (cancer of the bone, soft tissues, or connective tissue (e.g., tendon or cartilage)): 1 person, 7.69%
Metastases To Lung (cancer spreads to lung): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Halaven and have C-reactive protein increased?

- Check whether C-reactive protein increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Halaven:

Halaven (3,881 reports)

Browse all side effects of Halaven:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with C-reactive protein increased:

C-reactive protein increased (1,566 drugs)

Browse all the conditions that are associated with C-reactive protein increased:

C-reactive protein increased (2,281 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on eribulin mesylate (the active ingredients of Halaven) and Halaven (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.